Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Nivolumab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Feb 2024 New trial record